WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 207171
CAS#: 2569527-64-4
Description: HM43239 is an orally active small molecule inhibitor of FLT3 that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations. HM43239 directly inhibits the kinase activity of FLT3 as a reversible Type I inhibitor and effectively modulates downstream p-STAT5 and p-ERK. HM43239 also demonstrated inhibition of SYK, JAK1/2 and TAK1, known to be involved in tumor cell proliferation and/or differentiation HM43239 monotherapy induced dose-dependent regression of tumor growth in FLT3 wild-type and FLT3 mutated leukemia cancer cell line.
MedKoo Cat#: 207171
Name: HM43239
CAS#: 2569527-64-4
Chemical Formula: C29H33ClN6
Exact Mass: 500.2455
Molecular Weight: 501.075
Elemental Analysis: C, 69.51; H, 6.64; Cl, 7.07; N, 16.77
Related CAS #: 2294874-49-8
Synonym: HM43239; HM-43239; HM 43239; Tuspetinib
IUPAC/Chemical Name: rel-5-Chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)-2-pyrimidinamine
InChi Key: FZLSDZZNPXXBBB-KDURUIRLSA-N
InChi Code: InChI=1S/C29H33ClN6/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(35-28)34-23-10-20(9-22(11-23)21-5-6-21)16-36-14-18(2)33-19(3)15-36/h4,7-13,18-19,21,31,33H,5-6,14-16H2,1-3H3,(H,32,34,35)/t18-,19+
SMILES Code: CC1=CC2=C(C=C1)C(C3=NC(NC4=CC(CN5C[C@@H](C)N[C@@H](C)C5)=CC(C6CC6)=C4)=NC=C3Cl)=CN2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
Biological target: | HM43239 is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. |
In vitro activity: | HM43239 potently inhibited the growth of AML cell lines harboring FLT3 ITD mutation, such as MV4-11 (IC50: 1.3 nM), MOLM-13 (5.1 nM) and MOLM-14 (2.9 nM). Furthermore, HM43239 effectively inhibited the phosphorylation levels of FLT3 and of downstream kinases related with cell proliferation. Reference: Cancer Res. 2018 July 1;78(13_Supplement):804. https://doi.org/10.1158/1538-7445.AM2018-804 |
In vivo activity: | Furthermore, the combination treatment of HM43239 with various reagents (e.g., IAP inhibitor, chemotherapy, etc) demonstrated synergistic efficacy in mouse models, xenografted with both MV-4-11 and MOLM-13 cell lines without any significant toxicity. Reference: Cancer Res. 2019 July 1;79(13_Supplement):1293. https://doi.org/10.1158/1538-7445.AM2019-1293 |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 125.0 | 249.47 |
The following data is based on the product molecular weight 501.075 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | 1. Kim J, Bae I, Choi J, Kim M, Byun J, Moon M, Lee E, Kim Y, Kang H, Kim E, Jung S, Ahn Y, Kim Y, Suh K. Abstract 1293: HM43239, a novel FLT3 inhibitor in overcoming resistance for acute myeloid leukemia. Cancer Res. 2019 July 1;79(13_Supplement):1293. doi: 10.1158/1538-7445.AM2019-1293. 2. Lee M, Young E, Moon M, Byun J, Yu H, Kang S, Lee J, Lee K, Kim E, Lee H, Kim Y, Ahn Y, Suh K, Kim S. Abstract 804: Antitumor activity of the potent and novel FLT3 inhibitor HM43239 in acute myeloid leukemia. Cancer Res. 2018 July 1;78(13_Supplement):804. doi: 10.1158/1538-7445.AM2018-804. |
In vitro protocol: | 1. Kim J, Bae I, Choi J, Kim M, Byun J, Moon M, Lee E, Kim Y, Kang H, Kim E, Jung S, Ahn Y, Kim Y, Suh K. Abstract 1293: HM43239, a novel FLT3 inhibitor in overcoming resistance for acute myeloid leukemia. Cancer Res. 2019 July 1;79(13_Supplement):1293. doi: 10.1158/1538-7445.AM2019-1293. 2. Lee M, Young E, Moon M, Byun J, Yu H, Kang S, Lee J, Lee K, Kim E, Lee H, Kim Y, Ahn Y, Suh K, Kim S. Abstract 804: Antitumor activity of the potent and novel FLT3 inhibitor HM43239 in acute myeloid leukemia. Cancer Res. 2018 July 1;78(13_Supplement):804. doi: 10.1158/1538-7445.AM2018-804. |
In vivo protocol: | 1. Kim J, Bae I, Choi J, Kim M, Byun J, Moon M, Lee E, Kim Y, Kang H, Kim E, Jung S, Ahn Y, Kim Y, Suh K. Abstract 1293: HM43239, a novel FLT3 inhibitor in overcoming resistance for acute myeloid leukemia. Cancer Res. 2019 July 1;79(13_Supplement):1293. doi: 10.1158/1538-7445.AM2019-1293. 2. Lee M, Young E, Moon M, Byun J, Yu H, Kang S, Lee J, Lee K, Kim E, Lee H, Kim Y, Ahn Y, Suh K, Kim S. Abstract 804: Antitumor activity of the potent and novel FLT3 inhibitor HM43239 in acute myeloid leukemia. Cancer Res. 2018 July 1;78(13_Supplement):804. doi: 10.1158/1538-7445.AM2018-804. |
1. Kim J, Bae I, Choi J, Kim M, Byun J, Moon M, Lee E, Kim Y, Kang H, Kim E, Jung S, Ahn Y, Kim Y, Suh K. Abstract 1293: HM43239, a novel FLT3 inhibitor in overcoming resistance for acute myeloid leukemia. Cancer Res. 2019 July 1;79(13_Supplement):1293. doi: 10.1158/1538-7445.AM2019-1293.
2. Lee M, Young E, Moon M, Byun J, Yu H, Kang S, Lee J, Lee K, Kim E, Lee H, Kim Y, Ahn Y, Suh K, Kim S. Abstract 804: Antitumor activity of the potent and novel FLT3 inhibitor HM43239 in acute myeloid leukemia. Cancer Res. 2018 July 1;78(13_Supplement):804. doi: 10.1158/1538-7445.AM2018-804.